These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19995604)

  • 1. The influence of heterogeneous nucleation on the surface crystallization of guaifenesin from melt extrudates containing Eudragit L10055 or Acryl-EZE.
    Bruce CD; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Eur J Pharm Biopharm; 2010 May; 75(1):71-8. PubMed ID: 19995604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal growth formation in melt extrudates.
    Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aqueous film coating to reduce recrystallization of guaifenesin from hot-melt extruded acrylic matrices.
    Bruce CD; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Drug Dev Ind Pharm; 2010 Feb; 36(2):218-26. PubMed ID: 19877992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moisture plasticization for enteric Eudragit® L30D-55-coated pellets prior to compression into tablets.
    Rujivipat S; Bodmeier R
    Eur J Pharm Biopharm; 2012 May; 81(1):223-9. PubMed ID: 22269937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets.
    Schilling SU; Bruce CD; Shah NH; Malick AW; McGinity JW
    Int J Pharm; 2008 Sep; 361(1-2):158-68. PubMed ID: 18582547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of microparticles of naproxen with Eudragit RS and talc by spherical crystallization technique.
    Maghsoodi M; Esfahani M
    Pharm Dev Technol; 2009; 14(4):442-50. PubMed ID: 19235551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of guaifenesin and ketoprofen on the properties of hot-melt extruded polyethylene oxide films.
    Crowley MM; Fredersdorf A; Schroeder B; Kucera S; Prodduturi S; Repka MA; McGinity JW
    Eur J Pharm Sci; 2004 Aug; 22(5):409-18. PubMed ID: 15265510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Floating hot-melt extruded tablets for gastroretentive controlled drug release system.
    Fukuda M; Peppas NA; McGinity JW
    J Control Release; 2006 Oct; 115(2):121-9. PubMed ID: 16959356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture.
    Rumondor AC; Marsac PJ; Stanford LA; Taylor LS
    Mol Pharm; 2009; 6(5):1492-505. PubMed ID: 19634917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the re-crystallization behaviour of amorphous lactose using the RH-perfusion cell.
    Timmermann IL; Steckel H; Trunk M
    Eur J Pharm Biopharm; 2006 Aug; 64(1):107-14. PubMed ID: 16527465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of humidity on the disintegrant property of alpha-cellulose.
    Uhumwangho MU; Okor RS
    Acta Pol Pharm; 2005; 62(1):39-44. PubMed ID: 16022492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of accelerated storage conditions affecting physical characteristics, in-vitro dissolution and stability of bioadhesive containing tablets.
    Hosny EA
    Boll Chim Farm; 1999 Jun; 138(6):243-8. PubMed ID: 10464972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties of hot-melt extruded tablet formulations for the colonic delivery of 5-aminosalicylic acid.
    Bruce LD; Shah NH; Malick AW; Infeld MH; McGinity JW
    Eur J Pharm Biopharm; 2005 Jan; 59(1):85-97. PubMed ID: 15567305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The manufacture and characterisation of hot-melt extruded enteric tablets.
    Andrews GP; Jones DS; Diak OA; McCoy CP; Watts AB; McGinity JW
    Eur J Pharm Biopharm; 2008 May; 69(1):264-73. PubMed ID: 18164604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of melt extruded enteric matrix pellets.
    Schilling SU; Shah NH; Waseem Malick A; McGinity JW
    Eur J Pharm Biopharm; 2010 Feb; 74(2):352-61. PubMed ID: 19782133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the effect of temperature and moisture on the solid dispersions: aging and crystallization.
    Tian B; Zhang L; Pan Z; Gou J; Zhang Y; Tang X
    Int J Pharm; 2014 Nov; 475(1-2):385-92. PubMed ID: 25218489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanical properties of excipients do not affect polymer matrix formation.
    Chatterjee L; Rades T; Tucker IG
    Int J Pharm; 2010 Jan; 384(1-2):87-92. PubMed ID: 19819317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of polymer content on stabilizing milled amorphous salbutamol sulphate.
    Balani PN; Wong SY; Ng WK; Widjaja E; Tan RB; Chan SY
    Int J Pharm; 2010 May; 391(1-2):125-36. PubMed ID: 20211717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
    Sauer D; Zheng W; Coots LB; McGinity JW
    Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properties of sustained release hot-melt extruded tablets containing chitosan and xanthan gum.
    Fukuda M; Peppas NA; McGinity JW
    Int J Pharm; 2006 Mar; 310(1-2):90-100. PubMed ID: 16413153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.